Novavax, Inc.
Novavax, Inc.
NVAX

Novavax, Inc. (NVAX)

$51.430.81%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$49.29
Day's Range
$52.765
$34.88
52-Week Range
$277.8
1 month return6.29%
3 month return30.23%
1 year return75.91%
5 year return137.84%

Company Information

Novavax, Inc. is a biotechnology company focused on delivering novel products that effectively use innovative technology to solve known and emerging disease threats. The biotechnology giant is dedicated to creating cost-effective and democratized vaccine solutions for infectious diseases, such as seasonal flu, Ebola, COVID-19, and more. Founded in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland. It specializes in developing recombinant vaccines, and its lineup includes NVX-CoV2373, NanFlu, and ResVax, helpful in treating or preventing coronavirus, seasonal quadrivalent influenza, and a respiratory syncytial virus, respectively. Novavax, Inc. is also testing Matrix-M and its EBOV vaccine candidate in the Phase I clinical trial. It is also developing additional pre-clinical stage vaccine programs for occurrences such as MERS. It presently has over 750 employees, and its Nuvaxovid, a COVID-19 solution, is the fifth approved vaccine in the European Union. Further, Novavax has also filed the complete CMC data package with the FDA. It combines Novavax’s manufacturing prowess with Serum Institute of India Pvt. Ltd. (SII)’s experience for improved vaccine manufacturing. In addition, it also purchased Praha Vaccines and its vaccine factory in the Czech Republic, having a capacity of 1 billion doses per year. Currently Novavax, Inc. has a market cap of $4.21 Billion. It has a P.E ratio of -3.0. The shares of Novavax, Inc. are trading at $51.85. .
OrganizationNovavax, Inc.
Employees791
CEOStanley Erck
IndustryHealth Technology

Analyst Recommendation

based on 14 analysts ratings

Buy
71%
Buy
28%
Hold
0%
Sell

Based on 14 Wall street analysts offering stock ratings for Novavax, Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 278.01%

Current

$51.85

Target

$196.0

Recommendation Trend

Based on 14 analyst

Current1M Ago3M Ago
Buy
10
10
9
Hold
4
4
4
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
3.5B
Book Value
6.47
Dividend Share
0.0
Dividend Yield
0.0
Earnings Share
-23.44
PEG Ratio
0.0
Wall Street Target Price
170.33

Valuation

Trailing PE0.0
Forward PE1.34
Price/Sales (ttm)
3.09
Price/Book (mrq)
13.38
Enterprise Value
2.5B
Enterprise Value/Revenue
2.18
Enterprise Value/Ebitda
0.0

Technicals

Beta
1.33
50 Day MA
71.05
200 Day MA
150.41

Institutional Holdings

Vanguard Group Inc

8.92%

BlackRock Inc

5.63%

State Street Corporation

3.19%

Susquehanna International Group, LLP

1.7%

Geode Capital Management, LLC

1.28%

Morgan Stanley - Brokerage Accounts

1.22%

Discover more

Frequently Asked Questions

What is Novavax, Inc. share price today?

Can Indians buy Novavax, Inc. shares?

How can I buy Novavax, Inc. shares from India?

Can Fractional shares of Novavax, Inc. be purchased?

What are the documents required to start investing in Novavax, Inc. stocks?

What are today’s High and Low prices of Novavax, Inc.?

What are today’s traded volumes of Novavax, Inc.?

What is today’s market capitalisation of Novavax, Inc.?

What is the 52 Week High and Low Range of Novavax, Inc.?

How much percentage Novavax, Inc. is down from its 52 Week High?

How much percentage Novavax, Inc. is up from its 52 Week low?

What are the historical returns of Novavax, Inc.?

Who is the Chief Executive Officer (CEO) of Novavax, Inc.?